Revenue Performance - Total revenue for Q2 2024 was $28.3 million, a decrease of 3% year-over-year but an increase of 6% sequentially[6]. - Cell Processing revenue for Q2 2024 was $18.0 million, down 4% year-over-year but up 11% sequentially[6]. - Product revenue for the three months ended June 30, 2024, was $21,310, a decrease of 6.5% compared to $22,786 for the same period in 2023[23]. - Total revenue for the six months ended June 30, 2024, was $55,107, down 5.9% from $58,419 in the prior year[23]. - Total revenues for the three months ended June 30, 2024, were $28,328, a decrease of 3.1% from $29,237 for the same period in 2023[30]. Profitability Metrics - GAAP gross margin for Q2 2024 was 51%, an increase from 35% in Q2 2023; non-GAAP adjusted gross margin was 52%, up from 45%[8]. - Adjusted EBITDA for Q2 2024 was $4.8 million, or 17% of revenue, compared to $1.7 million, or 6% of revenue, in Q2 2023[12]. - Gross profit for the three months ended June 30, 2024, was $14,316, representing a gross margin of 51%, compared to a gross profit of $10,291 and a margin of 35% in the prior year[30]. - Adjusted gross profit for the three months ended June 30, 2024, was $14,868, with an adjusted gross margin of 52%, up from 45% in the same period last year[30]. - The company reported a gross margin of 51% for the six months ended June 30, 2024, compared to 40% for the same period in 2023[30]. Guidance and Expectations - The company raised its full-year 2024 revenue guidance to $99.0 million to $101.0 million, up from previous guidance of $95.5 million to $100.0 million[13]. - Cell Processing revenue guidance for 2024 was increased to $70.0 million to $71.0 million, representing a growth of 6% to 8% compared to 2023[13]. - Management expects full-year positive adjusted EBITDA and adjusted EBITDA growth in 2024[14]. Operating Expenses and Losses - Total operating expenses for the three months ended June 30, 2024, were $31,122, down from $39,865 in the same quarter of 2023[23]. - Research and development expenses for the three months ended June 30, 2024, were $2,382, a decrease of 37.2% compared to $3,793 in the same period of 2023[23]. - Operating loss for the three months ended June 30, 2024, was $(2,794), significantly improved from $(10,628) in the same quarter of 2023[23]. - The net loss from continuing operations for the three months ended June 30, 2024, was $(7,145), compared to a net loss of $(5,518) for the same period in 2023[33]. - The adjusted net loss from continuing operations for the six months ended June 30, 2024, was $(5,348), compared to $(11,446) in the same period last year[33]. Cash Flow and Financial Position - Cash used in operating activities for the six months ended June 30, 2024, was $1,984, a significant improvement from cash used of $(10,430) in the prior year[29]. - The company reported a net decrease in cash, cash equivalents, and restricted cash of $(13,393) for the six months ended June 30, 2024[29]. Product Development and Market Position - The company processed 12 new U.S. FDA Master File cross references for biopreservation media, bringing the cumulative total to 728[3]. - The biopreservation media is now embedded in 15 unique commercial CGTs, with expectations for 11 additional product approvals in the next 12 months[3]. - The company introduced the CellSeal CryoCase at the ISCT conference, aimed at replacing cryopreservation bags[3].

Revenue Performance - Total revenue for Q1 2024 was $31.727 million, a decrease of 16% from $37.703 million in Q1 2023[33] - Product revenue from freezers and thaw systems decreased by 33% to $8.334 million, down from $12.381 million[33] - Cell processing revenue declined by 15% to $16.186 million, compared to $18.993 million in the previous year[33] - Biostorage services revenue increased by 29% to $283,000 from $219,000 year-over-year[33] - Service revenue from biostorage services rose by 30% to $4.975 million, up from $3.825 million[33] - Product revenue decreased to $24,803,000 in Q1 2024 from $31,593,000 in Q1 2023, a decline of approximately 21.5%[80] - Total revenue for Q1 2024 was $31,727,000, down from $37,703,000 in Q1 2023, representing a decrease of about 16%[80] - Service revenue increased to $5,088,000 in Q1 2024 from $4,471,000 in Q1 2023, marking an increase of about 13.8%[80] - Revenue concentration from CryoStor was 41% for the three months ended March 31, 2024, compared to 44% for the same period in 2023[137] - The company reported that 80% of its revenue for the three months ended March 31, 2024, came from the United States, slightly up from 79% in the previous year[137] Financial Position - As of March 31, 2024, total long-term debt was $15.681 million, down from $18.311 million as of December 31, 2023[49] - Total short-term obligations as of March 31, 2024, were $10.0 million[40] - The estimated sales tax liability was approximately $5.0 million as of March 31, 2024[41] - As of March 31, 2024, total debt amounted to $24.3 million, with scheduled maturities of $5.975 million for 2024 and $10.511 million for 2025[51] - Total current assets decreased from $120.6 million as of December 31, 2023, to $111.7 million as of March 31, 2024[73] - Total liabilities decreased from $75.1 million as of December 31, 2023, to $68.2 million as of March 31, 2024[73] - Total shareholders' equity as of March 31, 2024, was $333.4 million, a decrease from $337.7 million as of December 31, 2023[75] - The company had 46,030,886 shares of common stock outstanding as of May 3, 2024[64] - The company reported a depreciation expense of $1,364,000 for the three months ended March 31, 2024, compared to $1,721,000 for the same period in 2023, indicating a 20.8% decrease[107] - The company’s total assets measured at fair value as of March 31, 2024, amounted to $32.661 million, compared to $41.870 million as of December 31, 2023[154] Cash Flow and Expenses - Cash and cash equivalents decreased from $35.4 million as of December 31, 2023, to $29.7 million as of March 31, 2024[73] - Cash used in operating activities for the three months ended March 31, 2024, was $4,475,000, compared to $2,712,000 for the same period in 2023, indicating a 64.9% increase in cash outflow[107] - The company’s cash flows from investing activities resulted in a net cash outflow of $221,000 for the three months ended March 31, 2024, compared to a net cash inflow of $2,926,000 in the same period of 2023[107] - The company’s cash interest paid for the three months ended March 31, 2024, was $445,000, a slight decrease from $497,000 in the same period of 2023[109] - The cash, cash equivalents, and restricted cash at the end of the period were $29,725,000, a decrease of $5,648,000 from the beginning of the period[109] - Net cash used by operating activities was $4.5 million in Q1 2024, up from $2.7 million in Q1 2023[210] Loss and Profitability - Net loss for Q1 2024 was $10,221,000, compared to a net loss of $13,714,000 in Q1 2023, showing an improvement of approximately 25.5%[83] - Operating loss improved to $(10,128,000) in Q1 2024 from $(13,605,000) in Q1 2023, reflecting a reduction of about 25.5%[80] - Basic and diluted net loss per share improved to $(0.22) in Q1 2024 from $(0.32) in Q1 2023, an improvement of about 31.3%[80] - The net loss for the three months ended March 31, 2024, was $10,221,000, an improvement from a net loss of $13,714,000 for the same period in 2023, representing a 25.3% decrease in losses[107] Stock Compensation and Equity - The company reported stock-based compensation of $6,183,000 for the three months ended March 31, 2024, down from $7,363,000 in the same period of 2023, reflecting a 16.0% decrease[107] - The aggregate fair value of service-based vesting awards granted was $3.2 million during Q1 2024[186] - Stock compensation expense related to service-based vesting awards was $4.7 million in Q1 2024, with $35.4 million in unrecognized compensation costs expected to be recognized over 2.6 years[187] - The company recognized stock compensation expense of $0.2 million related to performance-based restricted stock awards in Q1 2024, with $1.7 million in unrecognized costs expected to vest over 1.8 years[190] Divestiture and Future Outlook - The company divested Global Cooling, Inc. on April 17, 2024, impacting financial results as of March 31, 2024[28] - The company completed the divestiture of Global Cooling, Inc. on April 17, 2024, which will be reflected in future financial results[113] - The company anticipates that its current level of cash and liquid assets will be sufficient to meet liquidity needs for at least the next twelve months[133] - The company continues to face cost pressures and economic uncertainty affecting customer purchasing patterns, which may impact future revenue[134]

Financial Data and Key Metrics Changes - The company reported Q1 revenue of $31.7 million, a decrease of 16% year-over-year, primarily due to a 35% decrease in revenue from freezer products and a 15% decrease in the cell processing platform, partially offset by a 25% increase in the biostorage services platform [13][27] - Adjusted gross margin for Q1 was 40%, up from 37% in the prior year, attributed to a more favorable product mix and better utilization at biorepository facilities [27] - Adjusted EBITDA for Q1 was negative $1.2 million, compared to negative $1.1 million in the prior year, with a pro forma adjusted EBITDA excluding GCI being positive $3.6 million [28][18] Business Line Data and Key Metrics Changes - The cell processing revenue saw a sequential increase of 10%, following an 11% increase from Q3 to Q4 of the previous year [7] - The biostorage and services platform posted a 7% revenue growth over Q4 of the previous year [7] - The freezer assets, specifically CBS, represented approximately 11% of Q1 sales and have been a historical drag on profitability, with plans to exit this business [6] Market Data and Key Metrics Changes - The CGT regulatory environment showed momentum with biopreservation media embedded in two newly-approved therapies, bringing the total to 15 approved therapies supported by the company [20] - The company has a market share exceeding 70% in commercially-sponsored clinical trials in the U.S., with approximately 45 Phase 2 and Phase 3 trials utilizing its CryoStor product [42] Company Strategy and Development Direction - The company is focusing on high-margin cell processing and biostorage services, moving away from low-margin freezer products [4] - The divestiture of the GCI freezer unit is expected to enhance the financial profile and operations of the company [5] - The company aims to leverage its market-leading position in biopreservation to drive the adoption of high-margin recurring revenue tools and services [83] Management's Comments on Operating Environment and Future Outlook - Management expressed increased confidence in the full-year revenue outlook of $95.5 million to $100 million, indicating an easing macro environment in the bioproduction subsector [16] - The company anticipates continued revenue growth and margin expansion throughout 2024, driven by its cell processing and biostorage services platforms [52] Other Important Information - The company’s cash and marketable securities balance at March 31, 2024, was $46.1 million, down from $52.3 million at the end of 2023 [51] - The company expects to achieve adjusted EBITDA with a two in front of it by the end of next year, with potential for a three in front of it by early 2026 [56] Q&A Session Summary Question: Is there any update on the sale of CBS? - Management confirmed they are in the middle of the divestiture process and expect modest cash proceeds, with reduced operating expenses at CBS making it slightly positive from an adjusted EBITDA perspective [59] Question: What do you see on the competitive front? - The focus is on protecting and growing the biopreservation media position, ensuring the company remains a leader in this space [57] Question: How do you plan for the ramp of newly approved therapies? - The ramp is built into actual results and future forecasts, with better visibility indicating an improved forecast for customer adoption of therapies [66] Question: What is the expected lag between increased funding for customers and order flow? - The expected lag is approximately two to three quarters for orders to start flowing through after customers see increased funding [76] Question: What are the plans for future facility expansions? - The company is considering consolidating existing facilities to increase capacity, particularly in Boston and New Jersey [68]

Revenue Performance - Total revenue for Q1 2024 was $31.7 million, a decrease of $6.0 million, or 16%, from $37.7 million in Q1 2023[8] - Total revenue for the three months ended March 31, 2024, was $31,727,000, a decrease of 16% compared to $37,703,000 for the same period in 2023[32] - Product revenue decreased to $24,803,000, down 21.5% from $31,593,000 year-over-year[32] - Service revenue increased to $5,088,000, up 13.8% from $4,471,000 year-over-year[32] - The Biostorage Services platform revenue was $7.1 million, an increase of 25% from the same period in 2023[9] - Total revenue for the same period was $31,727,000, with revenue adjusted for Global Cooling at $26,779,000, indicating a significant contribution from other segments[54] Profitability and Loss - The net loss for Q1 2024 was $10.2 million, compared to a net loss of $13.7 million in Q1 2023[15] - Net loss attributable to common shareholders for the three months ended March 31, 2024, was $(10,221,000), compared to $(13,714,000) for the same period in 2023[32] - For the three months ended March 31, 2024, BioLife Solutions reported a net loss of $10,221,000, compared to a net loss of $13,714,000 for the same period in 2023, representing a 25.5% improvement[52] - Adjusted net loss for the three months ended March 31, 2024, was $(9,014,000), compared to $(10,601,000) for the same period in 2023[44] - The net loss adjusted for Global Cooling was $4,453,000, showing a reduction from the unadjusted net loss[56] Gross Margin and EBITDA - GAAP gross margin for Q1 2024 was 38%, up from 35% in Q1 2023, while adjusted gross margin (non-GAAP) improved to 40% from 37%[11] - Gross profit for the three months ended March 31, 2024, was $11,979,000, resulting in a gross margin of 38%, compared to a gross margin of 35% in the same period last year[46] - The adjusted gross profit excluding Global Cooling was $14,189,000, resulting in an adjusted gross margin of 53%[54] - Adjusted EBITDA for Q1 2024 was $3.6 million, compared to an adjusted EBITDA loss of $1.2 million when excluding GCI[3][7] - The adjusted EBITDA excluding Global Cooling was reported at $3,583,000, reflecting a positive operational performance[56] Cash and Assets - Cash, cash equivalents, and marketable securities as of March 31, 2024, totaled $46,126,000, down from $52,274,000 as of December 31, 2023[37] - Total assets as of March 31, 2024, were $401,602,000, a decrease from $412,714,000 at the end of 2023[37] - Current liabilities decreased to $38,658,000 from $42,178,000 at the end of the previous year[37] Strategic Initiatives - The company processed 22 new U.S. FDA Master File cross references for biopreservation media, bringing the total to 716[4] - BioLife Solutions affirmed its 2024 revenue guidance of $95.5 million to $100.0 million, with expectations for growth in both Cell Processing and Biostorage Services platforms[12] - The company completed the sale of Global Cooling, Inc. (GCI) on April 17, 2024, which transformed its financial profile[5] - Management expects full-year positive adjusted EBITDA and adjusted EBITDA growth in 2024[21] - The company continues to focus on enhancing its product offerings and market expansion strategies to drive future growth[56] Cost Management - Share-based compensation (non-cash) for the three months ended March 31, 2024, was $5,237,000, down from $7,363,000 in the previous year[56] - The company incurred acquisition and divestiture costs of $237,000 during the period, which is a decrease from $833,000 in the same quarter of the previous year[52] - The depreciation expense for the quarter was $1,434,000, compared to $1,731,000 in the prior year, indicating improved asset utilization[52] - Operating loss for the three months ended March 31, 2024, was $(10,128,000), an improvement from $(13,605,000) in the prior year[42]

Financial Data and Key Metrics Changes - Total revenue for 2023 was $143.3 million, an 11% decrease compared to 2022, with ex-COVID revenue decreasing 4% [10] - Q4 revenue was $32.7 million, representing a 26% year-over-year decrease, and a 23% decline when excluding COVID-related revenue from Q4 2022 [21] - Adjusted gross margin for Q4 was 35%, up from 32% in the prior year, primarily due to product mix and lower warranty expenses [23] - Adjusted operating loss for Q4 2023 was $9.3 million, compared to $8.2 million in Q4 2022 [25] - Adjusted EBITDA for Q4 2023 was $700,000, down from $1.7 million in the prior year but increased sequentially by $3.8 million from Q3 [26] Business Line Data and Key Metrics Changes - Cell processing platform revenue for 2023 declined 4% to $65.8 million, with a 6% decrease in biopreservation media revenue, partially offset by a 9% increase in other cell processing tools [10] - Biostorage and services platform revenue decreased 2% to $25.9 million, but grew 61% when excluding prior year COVID-related revenue [12] - Freezer and thaw platform revenue declined 23% to $15.1 million, primarily due to a difficult capital equipment environment [13] Market Data and Key Metrics Changes - The top 20 media customers accounted for 78% of media revenue, which was up slightly by 1% year-over-year [11] - Customers with commercially approved therapies accounted for an estimated 52% of direct media revenue in 2023, compared to 49% in 2022 [11] - The cell and gene therapy (CGT) industry is expected to grow at a 20% to 25% CAGR through 2033 [7] Company Strategy and Development Direction - The company is refocusing on higher margin recurring revenue streams and divesting freezer product lines to improve financial performance [6][14] - The company aims to leverage its market position in biopreservation media to drive adoption of other tools and services in its portfolio [89] - The 2024 revenue guidance is set between $95.5 million and $100 million, reflecting a cautious approach despite some optimism in market conditions [18] Management's Comments on Operating Environment and Future Outlook - Management noted that 2023 was a challenging year for the CGT industry, but there are early signs of stabilization and momentum [9] - The company expects a sustained recovery as 2024 progresses, with a focus on managing inventory normalization [9] - Management expressed confidence in the company's position to benefit from the growth of the CGT market, despite a cautious outlook for 2024 [89] Other Important Information - The company is in the process of divesting its freezer product lines, with two signed letters of intent (LOIs) and expects to close these transactions within 45 to 60 days [31][45] - The cash and marketable securities balance at December 31, 2023, was $52.3 million, up from $42.2 million at September 30, 2023 [27] Q&A Session Summary Question: Does the LOI allow the company to move the freezer assets to discontinued operations? - Management stated that a signed document is required to move them into discontinued operations, and they are working on finalizing the legal documents [31][32] Question: Can you discuss the steps taken to achieve positive EBITDA? - Management highlighted a reduction in force and control over discretionary expenses as key factors contributing to positive EBITDA [34][35] Question: How confident is the company about concluding the freezer sale? - Management expressed a 70% to 80% confidence level regarding the completion of the freezer sale within the expected timeframe [45][46] Question: What are the expectations for media revenue in 2024? - Management indicated that the first half of 2024 might be flat compared to the second half of 2023, with expectations of an uptake in the latter half [49] Question: What is the impact of the freezer business on adjusted EBITDA? - Management noted that they do not provide specific information on segment reporting but will clarify post-divestiture [81]

Financial Performance - Total revenue for the year ended December 31, 2023, was $143.3 million, a decrease of $18.5 million or 11% compared to $161.8 million in 2022[245]. - Product revenue from Freezer and thaw decreased by $16.1 million or 24% to $50.6 million in 2023, while Cell processing revenue decreased by $2.7 million or 4% to $65.8 million[245]. - The company reported a net loss of $66.4 million for the year ended December 31, 2023, with cash used in operating activities amounting to $12.5 million[259]. - Revenue concentration with one customer decreased to 16% in 2023 from 18% in 2022, indicating a more diversified customer base[278]. Expenses - General and administrative expenses increased by $8.1 million or 17% in 2023, primarily due to increased consulting fees related to strategic transactions[248]. - Sales and marketing expenses increased by $3.0 million, or 14%, in 2023, primarily due to increased stock compensation and advertising[280]. - Research and development expenses rose by $4.0 million, or 27%, in 2023, mainly due to increased stock-based compensation and scrapped materials for a future product[281]. Cash Flow and Liquidity - Cash and cash equivalents increased by $15.9 million or 82% to $35.4 million as of December 31, 2023, compared to $19.4 million in 2022[256]. - The company reported a net increase in cash and cash equivalents of $15.9 million in 2023, a significant improvement compared to a decrease of $50.3 million in 2022[290]. - Cash provided by financing activities was $10.6 million in 2023, primarily due to a private placement of $10.4 million[292]. - The company believes its liquidity requirements will be satisfied for at least the next twelve months through cash, cash equivalents, and credit lines[288]. Asset Impairment - The company recorded asset impairment charges of $15.5 million in the third quarter of 2023, compared to $69.9 million and $40.5 million in 2022[250]. - The Company recognized non-cash impairment charges totaling $15.5 million for definite-lived intangible assets as of September 30, 2023, including $9.7 million for property and equipment, $3.1 million for acquired technology, $0.2 million for customer relationships, and $2.5 million for tradename[319]. - The company experienced a non-cash impairment charge of $9.7 million on property and equipment and $5.8 million on definite-lived intangible assets due to market price decreases[318]. - The Company experienced a significant decline in market capitalization in 2022, leading to an interim quantitative impairment test for goodwill and intangible assets[321]. Strategic Plans and Transactions - The company plans to expand its cell and gene therapy tools and services business, focusing on sustaining product revenue and profits[265]. - The company is actively evaluating strategic transactions, including acquisitions of complementary products and technologies, which may require additional financing[266]. - The Sexton Merger had a fair value of net tangible assets acquired at approximately $4.1 million, with residual goodwill of approximately $28.5 million[267]. - The fair value of the net tangible assets acquired in the GCI Merger was $740,000, with residual goodwill of $137.8 million[300]. Fair Value and Currency Translation - The fair value of identifiable intangible assets is determined using an income approach, estimating after-tax cash flows and discounting them to present value[236]. - Fair value determinations are sensitive to changes in assumptions, with potential impairment risks for the Company's reporting unit and intangible assets if future growth rates and cash flows do not meet expectations[320]. - The month-end exchange rates indicated a decrease in translation of 2023 earnings into U.S. dollars by $150 million and a decrease in translation of net assets of foreign subsidiaries by $187 million[323]. - The company had U.S. federal net operating loss carryforwards of approximately $151.9 million as of December 31, 2023, with $39.2 million expiring from 2024 through 2037[243].

Company Overview - Origin Materials is described as the world's leading carbon negative materials company[1,28] - The company possesses disruptive materials technology and a decarbonizing platform technology[13] - The company's core technology is protected in key countries[29] Financial Performance & Outlook - Customer demand exceeds $10 billion, a tenfold increase since February 2021[9,17] - Q3 2023 revenue is expected to be $25 to $30 million[35] - Adjusted EBITDA loss for Q3 2023 is projected to be $45 million to $50 million[35] Technology & Production - Origin 1 has commenced commercial-scale production[31] - Timber feedstocks are approximately 10 times cheaper than bio alternatives[9] - The company holds 33 patent families as of November 9, 2023[9,13]

Financial Data and Key Metrics Changes - Adjusted operating expenses for Q3 2023 totaled $24.4 million, an increase from $20.8 million in the prior year, primarily due to $2.9 million in severance costs [1] - Adjusted EBITDA for Q3 2023 was negative $3.1 million compared to positive $1.8 million in the prior year, primarily due to lower biopreservation media revenue [79] - GAAP net loss was $29.1 million in Q3 2023, compared to $10.3 million in the prior year [54] Business Line Data and Key Metrics Changes - Revenue for the cell processing platform decreased by 26% year-over-year, with a 29% sequential decrease compared to Q2 [75][45] - Biostorage services platform revenue for Q3 was $6.6 million, a decrease of 10% year-over-year, but excluding COVID-related revenue from Q3 2022, revenue increased by 50% [76] - Freezers and Thaw Systems platform revenue for Q3 was $13.4 million, a decrease of 13% over the same period in 2022 [52] Market Data and Key Metrics Changes - The company expects to come in at the low end of its revenue guidance for 2023, projecting total revenue of approximately $144 million [3] - The company noted that macro headwinds and global economic uncertainties, including pharma destocking and a constrained biotech funding environment, have persisted throughout the third quarter [65] Company Strategy and Development Direction - The company is focused on divesting its freezer business to refocus on high-margin cell processing products and biostorage services [48] - The company aims to expand its biostorage capacity in existing locations and explore new strategic sites for further growth [72] - Management is optimistic about the growth potential in the cell and gene therapy market, with a focus on profitable growth [40][42] Management's Comments on Operating Environment and Future Outlook - Management believes that the challenges faced are transient and anticipates a recovery in customer orders as inventory levels normalize [111] - The company is confident that it will emerge stronger and more agile post-divestiture of the freezer business [30] - Management expressed enthusiasm about the opportunities ahead, particularly in the cell and gene therapy market [40] Other Important Information - The company reduced its corporate non-freeze operations headcount by 10% in anticipation of the divestiture [53] - Cash and marketable securities balance at September 30, 2023, was $42.2 million, down from $48.1 million at June 30, 2023 [55] Q&A Session Summary Question: What is the outlook for the fourth quarter? - Management indicated that they feel good about Q4 performance relative to guidance, with expectations for larger distributors and direct customers to recover [82] Question: Can you elaborate on the go-to-market strategy post-freezer sale? - The sales team will focus on scientifically oriented sales strategies for cell processing tools, differing from the capital equipment focus of the freezer sales team [83] Question: How is the freezer divestiture process progressing? - Management stated that the divestiture is likely to close in early 2024, with ongoing discussions with multiple parties [49][114] Question: What is the impact of the current biotech environment on long-term opportunities? - Management believes that the current challenges will not significantly impact their long-term opportunities in cell and gene therapy [139] Question: How will capital be deployed post-divestiture? - The focus will be on investing in product lines that are expected to drive profitable growth [140]

8 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------|-----------------------------------|-----------------------------------|-------|---------------------|---------------------|----------------------------|-------|----------------------------------------|---------------------|---------------|----------------------------| | (In thousands, except share data) | Series A Preferred Stock Shares | Series A Preferred Stock Amount | | Co ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Chad Wiatrowski – TD Cowen Amanda Young – KeyBanc Capital Markets Thomas Flaten – Lake Street Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Second Quarter 2023 Shareholders and Analyst ...